Dr. Renato G. Martins on Nivolumab and its Role as a Second-Line Treatment in NSCLC

Publication
Video
Special ReportsNSCLC (Issue 10)
Volume 10
Issue 10

​Renato G. Martins, MD, MPH, discusses why nivolumab is not ready to move up to being a firstline treatment in non

Renato G. Martins, MD, MPH, Medical Director, Thoracic/Head and Neck Medical Oncology, Seattle Cancer Care Alliance, discusses nivolumab in non—small cell lung cancer (NSCLC). Martins says while there are a number of trials where nivolumab is being combined with chemotherapy to increase its efficacy, the treatment is not ready for the firstline. He says until there is a reliable biomarker to identify which patients would benefit from the treatment, it would be difficult to move nivolumab into the frontline.

Related Videos
Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer
Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Related Content